Crossmark

Compound α-keto acid tablet supplementation alleviates chronic kidney disease progression via inhibition of the NF-kB and MAPK pathways

Crossref DOI link: https://doi.org/10.1186/s12967-019-1856-9

Published Online: 2019-04-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Meng

Xu, Huzi

Chong Lee Shin, Octavia Li-Sien

Li, Li

Gao, Hui

Zhao, Zhi

Zhu, Fan

Zhu, Han

Liang, Wangqun

Qian, Kun

Zhang, Chunxiu

Zeng, Rui

Zhou, Hanjing

Yao, Ying
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81570669)

National Natural Science Foundation of China (81770684)

National Natural Science Foundation of China (81570651)

National Natural Science Foundation of China (81770681)

Wuhan health and family planning commission (2016whzqnyxggrc2)
License Information

Text and Data Mining valid from 2019-04-11
More Information

Article History

Received: 5 December 2018

Accepted: 25 March 2019

First Online: 11 April 2019